Stockreport

Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company’s Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depress...

Artelo Biosciences, Inc.  (ARTL) 
US:NASDAQ Investor Relations: artelobio.com/investors
PDF SOLANA BEACH, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (“Artelo” or the “Company”) (Nasdaq: ARTL), a clinical-stage pharmaceutical company fo [Read more]